Mechanisms of Alcoholic Liver Disease

酒精性肝病的机制

基本信息

项目摘要

Alcohol consumption is a major etiology of chronic liver disease worldwide. The morphological spectrum of human alcoholic liver disease includes fatty liver, alcoholic hepatitis, and cirrhosis. In rodents, intragastric infusion of ethanol for 4-5 weeks leads to steatosis, inflammation, and to a less extent fibrosis in the liver, whereas feeding Lieber-DeCarli liquid diet containing ethanol does not cause significant liver injury except steatosis. In humans, interestingly, only a small percentage of heavy drinkers (10-15%) developed alcoholic liver injury, strongly suggesting that alcohol is a cofactor for developing chronic liver disease. Accumulating evidence suggests that many genetic and acquired factors are implicated in the susceptibility of the individual to alcohol-induced liver injury. It has been well documented that alcohol consumption accelerates the development and progression of liver disease induced by hepatitis virus infection. Our lab is to study how chronic ethanol consumption potentiates liver injury induced by other toxins or viruses and to study the molecular mechanisms underlying alcohol-induced liver injury. We have demonstrated that IL-6 plays an important role in protecting against liver injury in several murine models of alcoholic liver injury, nonalcoholic fatty liver disease, fatty liver transplantation, and T cell hepatitis. Our findings also showed that treatment with IL-6 ameliorates fatty liver disease in alcohol-fed mice, high-fatdiet fed mice, and genetically modified ob/ob mice. It is believed that the action of IL-6 is mediated via activation of signal transducer and activator of transcription 3 (STAT3). Currently, we are exploring the molecular mechanisms underlying the protective effect of IL-6 in fatty liver disease by using liver specific and macrophage/neutrophil-specific STAT3 knock out mice. In addition, we are also collaborating with Dr. George Kunos and Dr. Pal Pacher from NIAAA to investigate the role of canabinoid in alcoholic liver disease, and with Dr. Jake Liang from NIDDK to study the interaction of alcohol and hepatitis viral proteins in liver injury.
饮酒是全球慢性肝脏疾病的主要病因。人类酒精性肝病的形态学谱包括脂肪肝、酒精性肝炎和肝硬化。在啮齿类动物中,乙醇胃内输注4-5周会导致脂肪变性、炎症和较低程度的肝脏纤维化,而喂食含乙醇的Lieber-DeCarli液体饲料不会导致除脂肪变性外的显著肝损伤。有趣的是,在人类中,只有一小部分重度饮酒者(10-15%)会发生酒精性肝损伤,这强烈表明酒精是慢性肝病的辅助因素。越来越多的证据表明,许多遗传和获得性因素与个体对酒精诱导的肝损伤的易感性有关。有充分的证据表明,饮酒会加速肝炎病毒感染引起的肝病的发展和进展。我们的实验室研究慢性酒精消耗如何增强其他毒素或病毒引起的肝损伤,并研究酒精诱导的肝损伤的分子机制。我们已经证明IL-6在酒精性肝损伤、非酒精性脂肪性肝病、脂肪肝移植和T细胞肝炎的几种小鼠模型中对肝损伤起重要的保护作用。我们的研究结果还表明,用IL-6治疗可以改善酒精喂养的小鼠、高脂饮食喂养的小鼠和转基因ob/ob小鼠的脂肪肝疾病。据信IL-6的作用是通过激活信号转导子和转录激活子3(STAT 3)介导的。 目前,我们正在通过使用肝脏特异性和巨噬细胞/嗜中性粒细胞特异性STAT 3敲除小鼠来探索IL-6在脂肪肝疾病中保护作用的分子机制。 此外,我们还与NIAAA的乔治库诺斯博士和帕切尔博士合作,研究大麻素在酒精性肝病中的作用,并与NIDDK的杰克梁博士合作,研究酒精和肝炎病毒蛋白在肝损伤中的相互作用。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

bin gao其他文献

bin gao的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('bin gao', 18)}}的其他基金

ETHANOL AND IL6 SIGNAL TRANSDUCTION
乙醇和 IL6 信号转导
  • 批准号:
    2894248
  • 财政年份:
    1998
  • 资助金额:
    $ 60.01万
  • 项目类别:
TISSUE SPECIFIC CNTRL ALPHA 1B ANDRENOCEPTOR EXPRESSION
组织特异性 CNTRL ALPHA 1B 雄激素受体表达
  • 批准号:
    2633945
  • 财政年份:
    1998
  • 资助金额:
    $ 60.01万
  • 项目类别:
ETHANOL AND IL6 SIGNAL TRANSDUCTION
乙醇和 IL6 信号转导
  • 批准号:
    2558838
  • 财政年份:
    1998
  • 资助金额:
    $ 60.01万
  • 项目类别:
TISSUE SPECIFIC CNTRL ALPHA 1B ANDRENOCEPTOR EXPRESSION
组织特异性 CNTRL ALPHA 1B 雄激素受体表达
  • 批准号:
    6172833
  • 财政年份:
    1998
  • 资助金额:
    $ 60.01万
  • 项目类别:
TISSUE SPECIFIC CNTRL ALPHA 1B ANDRENOCEPTOR EXPRESSION
组织特异性 CNTRL ALPHA 1B 雄激素受体表达
  • 批准号:
    2895764
  • 财政年份:
    1998
  • 资助金额:
    $ 60.01万
  • 项目类别:
Innate immunity and cytokines in liver disease
肝病中的先天免疫和细胞因子
  • 批准号:
    8148175
  • 财政年份:
  • 资助金额:
    $ 60.01万
  • 项目类别:
Molecular Mechanism For Resistance To Interferon Therapy
干扰素治疗耐药的分子机制
  • 批准号:
    6675119
  • 财政年份:
  • 资助金额:
    $ 60.01万
  • 项目类别:
Immunologic Mechanisms of Alcoholic Liver Disease
酒精性肝病的免疫学机制
  • 批准号:
    8746472
  • 财政年份:
  • 资助金额:
    $ 60.01万
  • 项目类别:
Mechanisms of Alcoholic Liver Disease
酒精性肝病的机制
  • 批准号:
    7963847
  • 财政年份:
  • 资助金额:
    $ 60.01万
  • 项目类别:
Biological Significance and Therapeutic Potential of Cyt
细胞色素的生物学意义和治疗潜力
  • 批准号:
    6818687
  • 财政年份:
  • 资助金额:
    $ 60.01万
  • 项目类别:

相似海外基金

GPR35: mechanisms of action and agonism as a potential therapeutic strategy for non-alcoholic fatty liver diseases
GPR35:作为非酒精性脂肪肝疾病潜在治疗策略的作用和激动机制
  • 批准号:
    MR/X008827/1
  • 财政年份:
    2024
  • 资助金额:
    $ 60.01万
  • 项目类别:
    Research Grant
Perfluoroalkyl substances and non-alcoholic fatty liver disease in children: Leveraging magnetic resonance imaging to unravel potential mechanisms and exposure mixture effects
全氟烷基物质与儿童非酒精性脂肪肝:利用磁共振成像揭示潜在机制和暴露混合物效应
  • 批准号:
    10646759
  • 财政年份:
    2023
  • 资助金额:
    $ 60.01万
  • 项目类别:
Development of Early Diagnostic Markers for Non-Alcoholic Fatty Liver Disease (NAFLD) and Investigation of Inflammatory Mechanisms of NAFLD
非酒精性脂肪性肝病(NAFLD)早期诊断标志物的开发及NAFLD炎症机制的研究
  • 批准号:
    23K07466
  • 财政年份:
    2023
  • 资助金额:
    $ 60.01万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Bacteriotherapy to treat non-alcoholic fatty liver disease
细菌疗法治疗非酒精性脂肪肝
  • 批准号:
    2893992
  • 财政年份:
    2023
  • 资助金额:
    $ 60.01万
  • 项目类别:
    Studentship
Investigating folliculin as a regulator of VLDL-TG secretion in non-alcoholic fatty liver disease and steatohepatitis
研究卵泡素作为非酒精性脂肪肝和脂肪性肝炎中 VLDL-TG 分​​泌的调节剂
  • 批准号:
    10679361
  • 财政年份:
    2023
  • 资助金额:
    $ 60.01万
  • 项目类别:
The Gut-Liver Axis in HIV-Related Non-Alcoholic Fatty Liver Disease
HIV 相关非酒精性脂肪肝中的肠肝轴
  • 批准号:
    10762284
  • 财政年份:
    2023
  • 资助金额:
    $ 60.01万
  • 项目类别:
Epidemiology of diet, metabolism and non-alcoholic fatty liver disease in Hispanic/Latino adults
西班牙裔/拉丁裔成人饮食、代谢和非酒精性脂肪肝的流行病学
  • 批准号:
    10735454
  • 财政年份:
    2023
  • 资助金额:
    $ 60.01万
  • 项目类别:
Elucidation of molecular mechanisms of SBP1-based regulation of non-alcoholic fatty liver development/progression
阐明基于 SBP1 调节非酒精性脂肪肝发生/进展的分子机制
  • 批准号:
    23K10862
  • 财政年份:
    2023
  • 资助金额:
    $ 60.01万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Them1 Inhibitors for the Management of Non-Alcoholic Fatty Liver Disease
Them1 治疗非酒精性脂肪肝的抑制剂
  • 批准号:
    10666090
  • 财政年份:
    2023
  • 资助金额:
    $ 60.01万
  • 项目类别:
Uncovering the role of GPR75 as an activator of fatty acid transporters in non-alcoholic fatty liver disease (NAFLD)
揭示 GPR75 作为脂肪酸转运蛋白激活剂在非酒精性脂肪性肝病 (NAFLD) 中的作用
  • 批准号:
    10666762
  • 财政年份:
    2023
  • 资助金额:
    $ 60.01万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了